Organisation paid for research Program year 2025 Source: CMS Open Payments

Spectrum Clinical Rsrch

Neither a doctor nor a teaching hospital

Research payments

$368,700

400 payments

Through program year 2025, Spectrum Clinical Rsrch is reported as receiving $368,700 in research payments, across 400 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$221,087	170
2024	Research	$30,777	3
2020	Research	$49,019	72
2019	Research	$67,817	155

Breakdown

Who paid Research payments · program years 2019–2025

Boehringer Ingelheim International GmbH $310,943 386 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $57,756 14 payments

Studies the money was for Research payments · program years 2019–2025

EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) $221,087 170 payments
Empagliflozin and Heart failure (HFrEF) $81,039 124 payments
Empagliflozin and heart failure (HFpEF) $35,797 103 payments
BI 690517+Empa - Placebo+Empa in patients w. HF (LVEF) $30,777 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.